BillionToOne Q2 revenue rises 64% as test volumes grow
BLLN•Guidance reiterated for 2026
BillionToOne reiterated its 2026 revenue guidance of $450 million to $465 million.
The company expects to maintain profitability similar to current levels in 2026.
Growth drivers and analyst coverage
- Test volume growth — The company said a 35% increase in tests delivered drove higher Q2 revenue.
- Higher average selling price — A 21% year-over-year rise in ASP contributed to revenue and margin gains.
- Oncology segment expansion — Oncology clinical testing revenue rose 176%, though higher costs per test offset some margin gains.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for BillionToOne, Inc. is , about 15.6% below its August 4 closing price of .
